Document:

EX-10.1

 Exhibit 10.1 

Execution Version 

Confidential 
 Cooperation
Agreement 
 This Cooperation Agreement is made and entered into as of January 13, 2020 (this
“Agreement”) by and among Catalyst Biosciences, Inc., a Delaware corporation (the “Company”), and each of the parties listed on Exhibit A hereto (each, an
“Investor” and collectively, the “Investors”). The Company and the Investors are referred to herein as the “Parties.” 

Whereas, each of the Investors beneficially owns the number of shares of the Company’s common stock, par value $0.001 per share
(the “Common Stock”) listed on Exhibit A hereto; 
 Whereas, the Company has reached an
agreement with each of the Investors with respect to certain matters related to the Company’s board composition and certain other matters, as provided in this Agreement. 

Now, Therefore, in consideration of the premises and mutual covenants and agreements set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Investors, on a several and not joint basis, and the Company hereby agree as follows: 

Section 1.    Director Appointments. 

(a)    New Directors. Within five (5) business days of the execution of this Agreement, the Board of
Directors of the Company (the “Board”) shall irrevocably appoint Sharon Tetlow and Geoffrey Ling, M.D. (the “New Directors” and all references herein to the “New Directors”
shall include any Replacement Directors (as defined below)) as directors of the Company, effective January 15, 2020, with Ms. Tetlow becoming a Class III director whose term shall expire at the 2021 annual meeting of the
Company’s stockholders, and Dr. Ling becoming a Class I director whose term shall expire at the 2022 annual meeting of the Company’s stockholders. Immediately following Dr. Ling’s appointment as a New Director, the
Board shall take all necessary actions (including, if necessary, by unanimous written consent) to cause Dr. Ling to be appointed to one (1) committee or subcommittee of the Board that Dr. Ling requests to join, and any additional
committee or subcommittee participation shall be at the discretion of the Governance and Nominating Committee of the Board (the “Governance and Nominating Committee”). Each New Director has agreed in writing that he or she
understands and acknowledges that all members of the Board are required to comply with all policies, procedures, processes, codes, rules, standards and guidelines applicable to all Board members, including the Company’s code of business conduct
and ethics, securities trading policies, director confidentiality policies (including agreeing to preserve the confidentiality of Company business, information and discussions of matters considered in meetings of the Board or Board committees), and
corporate governance guidelines, in each case as heretofore provided to the New Directors. Each New Director and each Investor shall provide the Company with such information concerning such New Director or such Investor, as the case may be, as is
required to be disclosed under applicable law or stock exchange regulations, in each case as promptly as necessary to enable timely filing of the Company’s proxy statement. Each New Director shall also inform the Company of any financial
arrangements between any of the Investors and such New Director related to such New Director’s service with the Company, including without limitation any financial arrangement related to the Company’s market valuation or other financial
performance metrics. Notwithstanding anything herein to the contrary, the Investors shall have no liability hereunder with respect to any of the obligations of Ms. Tetlow or the Tetlow Replacement Director described under this Agreement, and
the failure of Ms. Tetlow and the Tetlow Replacement Director to comply with such obligations shall not be a breach or violation of this Agreement by the Investors. 

(b)    Board Composition. As promptly as practicable following the date of this Agreement, the Board shall
take all necessary actions to set the size of the Board at nine (9) members 

 
solely to accommodate the appointment of the New Directors in accordance with this Agreement. Immediately prior to the 2020 annual meeting of the Company’s stockholders (the “2020
Annual Meeting”), the Board shall take all necessary actions to (i) set the size of the Board at seven (7) members so that, assuming the election of each current Class II director standing for re-election, there are no vacancies on the Board and (ii) distribute the classes of directors of the Board as equally as possible; provided, however, that after giving effect to the foregoing the
New Directors shall remain members of the classes indicated for each thereof in Section 1(a). During the Standstill Period (as defined below) except as expressly stated above for the period before the 2020 Annual Meeting,
neither the Board nor any committee of the Board shall modify the size of the Board from seven (7) directors without the unanimous approval of the Board. 

(c)    Replacement Directors. 

(i)    During the Standstill Period, if Dr. Ling (or any Ling Replacement Director (as defined below)) is unable or
unwilling to serve as a director (including as a result of not being elected at any annual meeting), resigns as a director or is removed as a director, JDS1, LLC (“JDS1”) shall have the ability to recommend a substitute
person to replace Dr. Ling (or any Ling Replacement Director) in accordance with this Section 1(c)(i) (any such replacement director shall be referred to as the “Ling Replacement Director”).
Each candidate for Ling Replacement Director recommended by JDS1 must qualify as an “independent director” for purposes of the listing qualification rules of the Nasdaq Stock Market. The Governance and Nominating Committee shall consider
the qualifications and background of such candidate and make its determination and recommendation regarding whether such candidate is suitable for the Board within five (5) business days after such candidate has submitted to the Company any
documentation required by Section 1(a) herein. In the event the Governance and Nominating Committee does not accept a substitute person recommended by JDS1 as the Ling Replacement Director (given that the Governance and
Nominating Committee cannot unreasonably withhold its consent), JDS1 shall have the right to recommend additional substitute person(s) whose appointment shall be subject to the Governance and Nominating Committee recommending such person in
accordance with the procedures described above. Upon the recommendation of a Ling Replacement Director candidate by the Governance and Nominating Committee, the Board shall review, approve and vote on the appointment of such Ling Replacement
Director to the Board no later than five (5) business days after the Governance and Nominating Committee’s recommendation of such Ling Replacement Director; provided, however, that if the Board does not approve and appoint
such Ling Replacement Director to the Board, the Parties shall continue to follow the procedures of this Section 1(c)(i) until a Ling Replacement Director is approved and appointed to the Board. Notwithstanding the
foregoing, if JDS1 has followed the procedures set forth in this Section 1(c)(i) four times to replace Dr. Ling (or any Ling Replacement Director), the fourth candidate for Ling Replacement Director recommended by JDS1
shall be approved and appointed to the Board by the Board no later than five (5) business days after recommendation by JDS1, unless the Board reasonably and in good faith determines that such candidate lacks the appropriate experience to act as
a member of the board of directors of a public company in the industry in which the Company operates. 
 (ii)    During
the Standstill Period, if Ms. Tetlow (or any Tetlow Replacement Director (as defined below)) is unable or unwilling to serve as a director (including as a result of not being elected at any annual meeting), resigns as a director or is removed
as a director, the Board shall have the ability to recommend a substitute person to JDS1 to replace Ms. Tetlow (or any Tetlow Replacement Director) in accordance with this Section 1(c)(ii) (any such replacement
director shall be referred to as the “Tetlow Replacement Director” and, together with the Ling Replacement Director, the “Replacement Directors”). Each candidate for Tetlow Replacement Director
recommended by the Board must qualify as an “independent director” for purposes of the listing qualification rules of the Nasdaq Stock Market. JDS1 shall consider the qualifications and background of such candidate and make its

  
 2 

 
determination and recommendation regarding whether such candidate is suitable for the Board within five (5) business days after such candidate has submitted to the Company any documentation
required by Section 1(a) herein. In the event that JDS1 does not approve a substitute person recommended by the Board as the Tetlow Replacement Director (given that JDS1 cannot unreasonably withhold its consent), the Board
shall have the right to recommend additional substitute person(s) whose appointment shall be subject to JDS1 approving such person in accordance with the procedures described above. Upon the approval of a Tetlow Replacement Director candidate by
JDS1, the Board shall approve and vote on the appointment of such Tetlow Replacement Director to the Board no later than five (5) business days after JDS1’s approval of such Tetlow Replacement Director; provided, however,
that if the Board does not approve and appoint such Tetlow Replacement Director to the Board, the Parties shall continue to follow the procedures of this Section 1(c)(ii) until a Tetlow Replacement Director is approved and
appointed to the Board. Notwithstanding the foregoing, if the Board has followed the procedures set forth in this Section 1(c)(ii) four times to replace Ms. Tetlow (or a Tetlow Replacement Director), the fourth
candidate for Tetlow Replacement Director recommended by the Board shall be approved and appointed to the Board by the Board no later than five (5) business days after recommendation by the Board, unless JDS1 reasonably and in good faith
determines that such candidate lacks the appropriate experience to act as a member of the board of directors of a public company in the industry in which the Company operates. 

(iii)    JDS1’s rights set forth in this Section 1(c) shall terminate upon the earlier of
(i) the time at which JDS1, CCUR Holdings, Inc., Julian Singer and each of their Affiliates collectively hold less than 3% of the fully-diluted capital stock of the Company and (ii) the end of the Standstill Period (as defined below). 

Section 2.    2020 Annual Meeting. 

(a)    Director Nominees. Subject to the Investors complying with the terms of this Agreement, the Board
hereby agrees to nominate a slate of directors at the 2020 Annual Meeting which consists of (i) the Class II member(s) of the Board as of the date thereof, but excluding (iii) each of Jeff Himawan, Ph.D., a Class II
director of the Company, and John P. Richard, a Class II director of the Company (Messrs. Himawan and Richard referred to collectively as the “Departing Directors”). Each Departing Director’s term as a member of the
Board shall expire at the 2020 Annual Meeting. 
 (b)    Proposals. Subject to the Company complying with
the terms of this Agreement, each Investor hereby agrees not to, and to cause any Affiliate of such Investor not to, bring any business (including director nominees) or proposals before or at the 2020 Annual Meeting. 

(c)    Voting by Investors. At the 2020 Annual Meeting, each of the Investors agrees to vote all shares of
Common Stock beneficially owned by each Investor and its Affiliates (as defined below) (i) in favor of the election of any incumbent director nominated by the Board and (ii) otherwise in accordance with the Board’s recommendation on
all other ordinary course matters recommended for stockholder approval by the Board, including with respect to the auditor of the Company and any “say-on-pay” vote (items (i) and (ii) being
referred to herein as “Ordinary Matters”); provided, however, (x) in the event that Institutional Shareholders Services (ISS) recommends otherwise with respect to any such proposals (other than the election
of directors), each of the Investors shall be permitted to vote in accordance with the ISS recommendation and (y) nothing in this Agreement (including without limitation with respect to Section 3 below) shall restrict
an Investor from voting freely or taking any position in public or private on any stockholder approval for any extraordinary transaction, such as a merger, material acquisition or disposition, or a liquidation and winding up of the Company. 

  
 3 

 (d)    Definitions. As used in this Agreement: 

(i)    the term “Affiliate” shall have the respective meanings set forth in Rule 12b-2 promulgated by the Securities and Exchange Commission (the “SEC”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”); 

(ii)    the terms “beneficial owner” and “beneficial ownership” shall
have the same meanings as set forth in Rule 13d-3 promulgated by the SEC under the Exchange Act; and 

(iii)    the term “change of control” shall mean the sale of all or substantially all the assets
of the Company; any merger, consolidation or acquisition of the Company with, by or into another corporation, entity or person; or any change in the ownership of more than 50% of the voting capital stock of the Company in one or more related
transactions. 
 (iv)    the terms “person” or “persons” shall mean any
individual, corporation (including not-for-profit), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization or
other entity of any kind or nature. 
 Section 3.    Standstill. 

(a)    Standstill. Each Investor agrees that, for the period commencing on the date of this Agreement and
ending on the earliest of (i) the thirtieth (30th) calendar day preceding the opening of the nomination window for submission of director nominees at the Company’s 2021 Annual Meeting, (ii) a material breach by the Company of its
obligations under this Agreement which is not cured within five (5) business days after written notice from any Investor, (iii) an announcement by the Company of any type of transaction involving a change of control in the Company and
(iv) the adoption by the Board of any amendment to any of the organizational documents of the Company that would impair the ability of stockholders to submit director nominations in connection with stockholder meetings after the 2020 Annual
Meeting (the “Standstill Period”), neither it nor any of its Affiliates will, and it will cause each of its Affiliates not to, directly or indirectly, in any manner other than pursuant to
Section 6(c), acting alone or in concert with others: 
 (i)    submit any stockholder
proposal (pursuant to Rule 14a-8 promulgated by the SEC under the Exchange Act or otherwise) or any notice of nomination or other business for consideration, or nominate any candidate for election to the Board
(including by way of Rule 14a-11 of Regulation 14A), other than as expressly permitted by this Agreement; 

(ii)    engage in, directly or indirectly, any “solicitation” (as defined in Rule 14a-1 of Regulation 14A) of proxies (or written consents) or otherwise become a “participant in a solicitation” (as such term is defined in Instruction 3 of Schedule 14A of Regulation 14A under the
Exchange Act) in opposition to the recommendation or proposal of the Board, or recommend or request or induce or attempt to induce any other person to take any such actions, or seek to advise, encourage or influence any other person with respect to
the voting of the Common Stock (including any withholding from voting) or grant a proxy with respect to the voting of the Common Stock or other voting securities to any person other than to the Board or persons appointed as proxies by the Board;

 (iii)    seek to call, or to request the call of, a special meeting of the Company’s stockholders, or make a
request for a list of the Company’s stockholders or for any books and records of the Company; 
 (iv)    form,
join in or in any other way participate in a “partnership, limited partnership, syndicate or other group” within the meaning of Section 13(d)(3) of the Exchange Act with respect to the Common Stock or deposit any shares of Common
Stock in a voting trust or similar arrangement or subject any shares of Common Stock to any voting agreement or pooling arrangement, other than a group consisting only of some or all of the Investors and their Affiliates; 

  
 4 

 (v)    vote for any nominee or nominees for election to the Board,
other than those nominated or supported by the Board; 
 (vi)    except as specifically provided in
Section 1 and Section 2 of this Agreement, seek to place a representative or other Affiliate or nominee on the Board or seek the removal of any member of the Board or a change in the size or
composition of the Board; 
 (vii)    acquire or agree, offer, seek or propose to acquire, or cause to be acquired,
ownership (including beneficial ownership) of any of the assets or business of the Company or any rights or options to acquire any such assets or business from any person, in each case other than securities of the Company; 

(viii)    other than at the direction of the Board, seek, propose or make any statement (other than to one or more
members of the Board or management or its advisors or agents) with respect to, or solicit, or negotiate with or provide any information to any person with respect to, a merger, consolidation, acquisition of control or other business combination,
tender or exchange offer, purchase, sale or transfer of assets or securities, dissolution, liquidation, reorganization, change in structure or composition of the Board, change in the executive officers of the Company, change in capital structure,
recapitalization, dividend, share repurchase or similar transaction involving the Company, its subsidiaries or its business, whether or not any such transaction involves a change of control of the Company (it being understood that the foregoing
shall not restrict the Investors from tendering Common Stock, receiving payment for Common Stock or otherwise participating in any such transaction on the same basis as other stockholders of the Company, or from participating in any such transaction
that has been approved by the Board); 
 (ix)    acquire, announce an intention to acquire, offer or propose to
acquire, or agree to acquire, directly or indirectly, by purchase or otherwise, beneficial ownership of (A) any interests in the Company’s indebtedness or (B) an aggregate amount of more than 14.99% of the Company’s outstanding
Common Stock (which shall not include Common Stock issued in connection with a stock split, stock dividend or similar corporate action initiated by the Company with respect to any securities beneficially owned by any of the Investors or their
Affiliates); provided, however, nothing herein shall prevent any Investor from confidentially seeking a waiver from this provision; 

(x)    short sell the Company’s capital stock, or otherwise pledge, hypothecate or put any liens against the
Company’s capital stock, except that an Investor may partake in customary margin transactions with a broker regulated by FINRA; 

(xi)    disclose publicly, or privately in a manner that could reasonably be expected to become public, any intention,
plan or arrangement inconsistent with the foregoing; 
 (xii)    take any action challenging the validity or
enforceability of any provisions of this Section 3; or 
 (xiii)    enter into any agreement,
arrangement or understanding concerning any of the foregoing (other than this Agreement) or encourage or solicit any person to undertake any of the foregoing activities. 

  
 5 

 (b)    Notwithstanding anything to the contrary herein, including,
without limitation, Section 6, nothing in this Agreement shall prohibit or restrict (i) any director of the Company, including any New Director, from exercising his or her rights and fiduciary duties as a director of
the Company (it being recognized that this clause shall not limit each director’s duty to comply with Board policies regarding confidentiality applicable to all members of the Board, including the obligation to refrain from sharing confidential
information of the Company with third parties without the prior authorization of the Board); or (ii) any New Director, or separately, any Investor or its directors, officers, partners, employees, members or agents (acting in such capacity)
(“Investor Representatives”) from communicating privately regarding or privately advocating for or against any of the matters described in this Section 3 or otherwise regarding the management,
strategy, business or operations of the Company with, or from privately requesting a waiver of any of the foregoing provisions of this Section 3 from, the Company’s directors, officers or agents, (it being recognized
that no officer, director or agent of the Company shall be under any obligation under this Agreement to communicate with any Investor or any director, officer, partner, employee, member or agent thereof); provided, however, that for
each of sub-sections (i) and (ii) above, in each case, so long as such communications or requests are not intended to, and would not reasonably be expected to, require any public disclosure of such
communications or requests. 
 (c)    During the Standstill Period, the Company agrees that, other than in any manner
expressly allowed pursuant to Section 6(c): 
 (i)    the Board will not create any
“executive committee” of the Board, or delegate to any existing or new committee of the Board, responsibilities substantially similar to those of an executive committee; 

(ii)    the Board and each committee and subcommittee of the Board shall ensure that during the Standstill Period the
existing responsibilities of any existing or new committee of the Board are not materially changed amongst such committees or delegated to any new committee, provided that for the sake of clarity, the Board may expand the duties of a given existing
committee so long as such new duties are not already the responsibility of an existing committee and do not violate the prohibition in Section 3(c)(i); 

(iii)    until the appointment of the New Directors, the Board will not amend any existing, or create any new agreement,
policy, code and guideline applicable to non-employee directors of the Company, including those regarding confidentiality (collectively the “Guidelines”); 

(iv)    if the Company engages in any equity financing (including without limitation the sale of any warrant, option or
other convertible security) other than an Excluded Transaction, the Company will use commercially reasonable efforts, including without limitation contacting the Investor by phone and email (it being understood that notice of less than twenty four
hours may be reasonable depending on the nature of the financing), to enable the Investor to participate in such financing up to such Investor’s pro rata amount of the shares offered in such financing based on Investor’s ownership of
outstanding shares of the Company’s common stock at such time, and subject to cutback of such Investor’s participation in the financing if the Company determines in good faith that such participation would jeopardize the offering. An
“Excluded Transaction” means (a) the issuance of shares of capital stock upon the exercise of any warrants outstanding as of the date hereof, (b) the issuance of shares of capital stock upon the exercise of any options issuance
pursuant to any management incentive plan or arrangement approved by the Board of Directors or stockholders of the Company, (c) the issuance of shares of capital stock in connection with any acquisition, licensing agreement, distribution, joint
venture or other commercial or collaborative relationship or (d) the issuance of shares of capital stock in any “at the market” arrangement; and 

  
 6 

 (v)    the Company shall notify the Investors promptly, but in any
event within five (5) business days, upon any breach by the Company of this Agreement. 

Section 4.    Representations and Warranties of the Company. The Company
represents and warrants to the Investors that (a) the Company has the corporate power and authority to execute this Agreement and to bind it thereto, (b) this Agreement has been duly and validly authorized, executed and delivered by the
Company, constitutes a valid and binding obligation and agreement of the Company, and is enforceable against the Company in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles, (c) the Company has provided the Investors with true and complete copies of the Guidelines prior to the date
hereof, (e) there is currently no “executive committee” of the Board, or committee of the Board with responsibilities similar to those of an executive committee, and (f) the execution, delivery and performance of this Agreement
by the Company does not and will not violate or conflict with (i) any law, rule, regulation, order, judgment or decree applicable to it, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or
lapse of time or both could become a default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, or any material
agreement, contract, commitment, understanding or arrangement to which the Company is a party or by which it is bound. 

Section 5.    Representations, Warranties and Covenants of the Investors. Each
Investor, on behalf of itself, severally and not jointly represents and warrants to the Company that (a) as of the date hereof, such Investor beneficially owns only the number of shares of Common Stock as described opposite its name on
Exhibit A, and Exhibit A includes all Affiliates of any Investors that own any securities of the Company beneficially or of record, (b) this Agreement has been duly and validly authorized, executed and delivered by
such Investor, and constitutes a valid and binding obligation and agreement of such Investor, enforceable against such Investor in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles, (c) such Investor has the authority to execute this Agreement on behalf of itself and the
applicable Investor associated with that signatory’s name, and to bind such Investor to the terms hereof, (d) the execution, delivery and performance of this Agreement by such Investor does not and will not violate or conflict with
(i) any law, rule, regulation, order, judgment or decree applicable to it, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could become a default) under or
pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which such
member is a party or by which it is bound and (e) no Investor has entered into any compensation arrangement with a New Director related to the Company. Each Investor further agrees until the Company’s 2021 Annual Meeting, each such
Investor shall not enter into any compensation arrangement with a New Director (or any substitute therefor) related to the Company. 

Section 6.    Mutual Non-Disparagement.
 
 (a)    Investor Non-Disparagement. Each Investor agrees
that, during the Standstill Period, neither it nor any of its Affiliates will, and it will cause each of its Affiliates not to, directly or indirectly, in any capacity or manner, publicly, by press release or similar public statement to the press,
securities analysts or media, or in any SEC filing, make, express, transmit speak, write, verbalize or otherwise communicate in any way (or cause, further, assist, solicit, encourage, support or participate in any of the foregoing), any remark,
comment, message, information, declaration, communication or other 

  
 7 

 
statement of any kind, whether verbal, in writing, electronically transferred or otherwise, that might reasonably be construed to be derogatory or critical of, or negative toward, the Company or
any of its directors, officers, Affiliates, subsidiaries, employees, agents or representatives (collectively, the “Company Representatives”), or that reveals, discloses, incorporates, is based upon, discusses, includes or
otherwise involves any confidential or proprietary information of the Company or its subsidiaries or Affiliates, or to malign, harm, disparage, defame or damage the reputation or good name of the Company, its business or any of the Company
Representatives. 
 (b)    Company Non-Disparagement. The Company
hereby agrees that, during the Standstill Period, neither it nor any of its Affiliates will, and it will cause each of its Affiliates not to, directly or indirectly, in any capacity or manner, publicly, by press release or similar public statement
to the press, securities analysts or media, or in any SEC filing, make, express, transmit, speak, write, verbalize or otherwise communicate in any way (or cause, further, assist, solicit, encourage, support or participate in any of the foregoing),
any remark, comment, message, information, declaration, communication or other statement of any kind, whether verbal, in writing, electronically transferred or otherwise, that might reasonably be construed to be derogatory or critical of, or
negative toward, any Investor or any Investor Representatives, or that reveals, discloses, incorporates, is based upon, discusses, includes or otherwise involves any confidential or proprietary information of any Investor or its subsidiaries or
Affiliates, or to malign, harm, disparage, defame or damage the reputation or good name of any Investor or Investor Representatives. 

(c)    Exceptions. Notwithstanding the foregoing, nothing in this Section 6 or
elsewhere in this Agreement, including without limitation, Section 3, shall prohibit any Party from (1) announcing its views and vote on any Board-approved publicly announced proposals relating to any non-Ordinary Matters, so long as such announcement is limited to the merits of any such matter and does not disparage the Company’s directors or officers in connection with such matter, including the decision
to pursue, approve or propose such matter, (2) making any statement consented to in writing by such other Parties, or (3) making any statement or disclosure required under the federal securities laws or other applicable laws;
provided, that such Party shall use reasonable best efforts to provide notice to the other Parties prior to making any such statement or disclosure required under the federal securities laws or other applicable laws that would otherwise be
prohibited by the provisions of this Section 6, and use reasonable best efforts to consider any comments of such other Parties. 

Section 7.    Public Announcements. No later than 5:00 p.m. Pacific time, on
Friday January 17, 2020, the Company shall issue a press release in form and substance reasonably agreed between the Parties (the “Agreement Press Release”). No Party or any of its Affiliates shall make any public
statement (including, without limitation, in any filing required under the Exchange Act) concerning the subject matter of this Agreement inconsistent with this Agreement and the Agreement Press Release. 

Section 8.    Expenses. Each Party shall be responsible for its own fees and
expenses incurred in connection with the negotiation, execution and effectuation of this Agreement and the transactions contemplated hereby. 

Section 9.    Specific Performance. Each of the Investors, on the one hand, and
the Company, on the other hand, acknowledges and agrees that irreparable injury to the other Party hereto may occur in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or are otherwise
breached and that such injury would not be adequately compensable in monetary damages. It is accordingly agreed that the Investors or any Investor, on the one hand, and the Company, on the other hand (the “Moving Party”),
shall each be entitled to seek specific enforcement of, and injunctive or other equitable relief to prevent any violation of, the terms hereof, and the other party hereto will not take action, directly or indirectly, in opposition to the Moving
Party seeking such relief on the grounds that any other remedy or relief is available. 
  

  
 8 

 Section 10.    Notice. Any
notices, consents, determinations, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; or
(ii) one (1) business day after deposit with a nationally recognized overnight delivery service and concurrently sent by e-mail, in each case properly addressed to the party to receive the same. The
addresses and e-mail addresses for such communications shall be: 
 To the Company: 

Catalyst Biosciences, Inc. 

Attention: Nassim Usman 
 611
Gateway Blvd., Suite 710 
 South San Francisco, CA 94080 

Telephone: (650) 871-0761 

E-mail: nusman@catbio.com 

with a copy to (which shall not constitute notice): 

Orrick, Herrington & Sutcliffe LLP 

Attention: Stephen Thau 
 Columbia
Center 
 1152 15th Street, N.W. 

Washington, D.C. 20005 

Telephone: (202) 339-8677 

E-mail: sthau@orrick.com 

To the Investors:    As set forth in the respective addresses listed in Exhibit A hereto. 

Section 11.    Governing Law. This Agreement shall be governed by, and construed
in accordance with, the law of the State of Delaware, without regard to conflict of law principles thereof, and each Party irrevocably submits to the personal jurisdiction of the Chancery Court of Delaware as the exclusive venue for adjudication of
any dispute hereunder.
 Section 12.    Entire Agreement. This Agreement
constitutes the full and entire understanding and agreement among the Parties with regard to the subject matter hereof, and supersedes all prior agreements with respect to the subject matter hereof. The Company may enter into a materially similar
agreement with one or more other investors but any such agreement shall constitute a separate obligation and one investor shall not become a third party beneficiary of another investor’s agreement. 

Section 13.    Receipt of Adequate Information; No Reliance; Representation by
Counsel. Each Party acknowledges that it has received adequate information to enter into this Agreement, that it has not relied on any promise, representation or warranty, express or implied not contained in this Agreement and that it has
been represented by counsel in connection with this Agreement. Accordingly, any rule of law or any legal decision that would provide any party with a defense to the enforcement of the terms of this Agreement against such party shall have no
application and is expressly waived. The provisions of this Agreement shall be interpreted in a reasonable manner to effect the intent of the Parties. 

  
 9 

 Section 14.    Severability. If
any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement shall remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only
in part or degree shall remain in full force and effect to the extent not held invalid or unenforceable. The Parties further agree to replace such invalid or unenforceable provision of this Agreement with a valid and enforceable provision that will
achieve, to the extent possible, the purposes of such invalid or unenforceable provision. 

Section 15.    Liability. For the avoidance of doubt, the Investors are entering
into this Agreement on a several and not joint basis. Any liability arising hereunder with respect to a specific Investor shall only apply to such specific Investor and shall not be shared among the other Investors party hereto. 

Section 16.    Amendment. This Agreement may be modified, amended or otherwise
changed only in a writing signed by all of the Parties. 

Section 17.    Termination. This Agreement shall terminate at the end of the
Standstill Period or other date established by mutual written agreement of the Parties hereto. Notwithstanding the foregoing, the provisions of Section 8 thru Section 19 shall survive the
termination of this Agreement. No termination of this Agreement shall relieve any Party from liability for any breach of this Agreement prior to such termination. 

Section 18.    Successors and Assigns; No Third Party Beneficiaries. This
Agreement shall bind the successors and permitted assigns of the Parties, and inure to the benefit of any successor or permitted assign of any of the Parties; provided, however, that no party may assign this Agreement without the prior
written consent of the other Parties. No provision of this Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities hereunder upon any person other than the Parties hereto and their respective successors and
assigns. 
 Section 19.    Counterparts. This Agreement may be signed in any
number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each Party hereto shall have received a counterpart
hereof signed by the other Parties hereto. Counterparts delivered by electronic transmission shall be deemed to be originally signed counterparts. 

(Signature page follows) 

  
 10 

 In Witness Whereof, the Parties hereto have duly executed and delivered this
Agreement as of the date first above written. 
  

			
	Catalyst Biosciences, Inc.
		
	By:	 	 /s/ Nassim Usman

	Name:	 	Nassim Usman
	Title:	 	President and Chief Executive Officer

  
 Signature Page to the
Cooperation Agreement 

 Investors: 

JDS1, LLC 
  

			
	By:	 	 /s/ Julian Singer

	Name:	 	Julian Singer
	Title:	 	Managing Member

  
 Signature Page to the
Cooperation Agreement 

 Investors: 
  

	
	 /s/ Julian Singer

	Julian Singer

  
 Signature Page to the
Cooperation Agreement 

 Investors: 
  

			
	By:	 	 /s/ David Oros

	Name:	 	David Oros
	Title:	 	

  
 Signature Page to the
Cooperation Agreement 

 Investors: 
  

	
	 /s/ Wayne Barr, Jr.

	Wayne Barr, Jr.

  
 Signature Page to the
Cooperation Agreement 

 Investors: 
  

			
	CCUR HOLDINGS, INC.
		
	By:	 	 /s/ Wayne Barr, Jr.

	Name:	 	Wayne Barr, Jr.
	Title:	 	President

  
 Signature Page to the
Cooperation Agreement 

 Exhibit A 

 

							
	 Investor
	  	Shares of Common
Stock
Beneficially Owned	 	  	 Notice

	 JDS1, LLC
	  	 	398,838	 	  	2200 Fletcher Avenue, Suite 501
Fort Lee, New Jersey 07024
Telephone:
201-592-3400
E-mail: julian@remusllc.com
			
	 CCUR Holdings, Inc.
	  	 	150,000	 	  	4375 River Green Parkway, Suite 210
Duluth, Georgia 30096
Telephone:
919-605-8142
E-mail: wayne.barr@ccurholdings.com
			
	 David S. Oros
	  	  	327,942	1 	  	702 W. Lake Avenue
Baltimore, Maryland 21210
Telephone: 443-386-0300
E-mail:
doros@gamma3ll.com
			
	 Julian Singer
	  	 	398,838	 	  	2200 Fletcher Avenue, Suite 501
Fort Lee, New Jersey 07024
Telephone:
201-592-3400
E-mail: julian@remusllc.com
			
	 Wayne Barr, Jr.
	  	 	150,000	 	  	4375 River Green Parkway, Suite 210
Duluth, Georgia 30096
Telephone:
919-605-8142
E-mail: wayne.barr@ccurholdings.com

  

	1 	 Note that this amount excludes 50,500 shares underlying call options that expire March 20, 2020. Such
shares are deemed to be beneficially owned but are not votable unless such options are exercised.Exhibit 10.1

 

TRANSITION AND SEPARATION AGREEMENT

 

This Transition and
Separation Agreement (hereafter, “Agreement”) is entered into by and between CYRUSONE LLC, a Delaware limited
liability company (hereafter, “Employer”), and Venkatesh S. Durvasula (hereafter, “Employee”)
on January 13, 2020 (hereafter, the “Effective Date”) based on the following facts:

 

WHEREAS, Employee
was initially employed by Employer as its Chief Commercial Officer pursuant to that certain Employment Agreement by and between
Employer and Employee dated as of January 24, 2013 (the “Employment Agreement”) and, pursuant to that certain
offer letter dated as of November 6, 2018 (the “Offer Letter”) has been employed by Employer as its President
- Europe; and

 

WHEREAS, Employer
has decided to terminate Employee’s employment pursuant to Section 13(d) of the Employment Agreement, effective as of March
1, 2020 (the “Termination Date”); and

 

WHEREAS, Following
the Termination Date, Employer desires to assure itself of Employee’s services for certain transition-related consulting
projects, and Employee desires to serve in this capacity under the terms and conditions hereinafter provided commencing on March
2, 2020 and continuing through June 30, 2020 (the “Consulting Period”); and

 

WHEREAS, in
order to induce Employee to faithfully and diligently perform his assigned duties and transfer his knowledge, skills, and business
experience to others at Employer prior to the Termination Date and to provide consulting services through the end of Consulting
Period, Employer has agreed to Employee certain related compensation and benefits as set forth in this Agreement; and

 

WHERAS, following
the Termination Date, Employer will provide the severance and related benefits described in Section 13(d) of the Employment Agreement,
subject to the terms and conditions outlined in such section and the terms of this Agreement; and

 

WHEREAS, pursuant
to Section 13(g) of the Employment Agreement, the parties now wish to memorialize the terms of their mutual agreement regarding
the termination of Employee’s employment and to fully and finally resolve any differences between them, including any and
all claims and controversies arising out of the employment relationship between Employer and Employee, that may have arisen, or
which may arise, prior to or at the Effective Date.

 

NOW THEREFORE,
in consideration of the foregoing and the mutual promises set forth below, the parties agree as follows:

 

		1.	Termination of Employment; Consulting Services.

 

		A.	Employee’s employment with Employer and its affiliates (collectively, the “CyrusOne
Group”) will terminate under Section 13(d) of the Employment Agreement, effective as of the Termination Date. Employer
will pay Employee for all hours worked through the Termination Date in accordance with Employer’s regular payroll procedures
and schedule; Employee acknowledges that these amounts are all of the amounts owed to him by Employer through the Termination Date.
As of the Termination Date, Employee’s status as an employee and executive officer of Employer shall cease. To the extent
there is any requirement that Employer give written or advance notice to Employee of the termination of Employee’s employment,
Employee waives such notice requirement. From and after the Termination Date, Employee is not to hold himself out as an employee,
member of the Employer’s Board of Directors, agent, or authorized representative of Employer, negotiate or enter into any
agreements on behalf of Employer, or otherwise attempt to bind Employer.

 

     

     

    

 

		B.	During the Consulting Period, Employee will be retained as a consultant to Employer and will perform
such other transition-related duties as may be specified by Employer’s Chief Executive Officer (or his/her designee) subject
to the terms set forth below.

 

		i.	Employee will not be required to regularly report to work during the Consulting Period but agrees
that he will make himself available to Employer, during regular business hours, as specified by Employer’s Chief Executive
Officer (or his/her designee) on an as-needed basis for project work, knowledge transfer and information exchange.
It is agreed by the parties that the level of services Employee will be requested to perform during the Consulting Period shall
be no greater than twenty percent (20%) of the average level of services Employee performed as an employee during the thirty-six
(36) month immediately preceding the Termination Date. Employee shall perform consulting services as an independent contractor,
and nothing contained herein shall operate, nor shall be construed to operate, as creating a relationship of employment, partnership,
joint venture or any other relationship except the relationship specifically set forth herein.

 

		ii.	As the sole consideration for his services during the Consulting Period, Employee shall be entitled
to a one-time payment of three hundred and sixty six thousand six hundred and sixty six dollars ($366,666.00), to be made on February
15, 2020, net of all applicable withholdings.

 

		2.	Benefits Coverage. Except as otherwise provided herein, prior to the Termination Date, Employee
shall generally remain eligible to participate in the employee benefit plans and programs maintained by CyrusOne Group, subject
to their applicable terms and conditions. Effective on the Termination Date and continuing through the Consulting Period and thereafter,
Employee’s participation in and eligibility for any employee or fringe benefit, compensation, bonus, or equity plans, programs,
or policies of CyrusOne Group will cease, subject to the applicable terms and conditions of any such plans, programs, and policies.
Employee’s entitlement to any payments or benefits after the Termination Date and/or during the Consulting Period under any
incentive pay or equity plans or programs in which he participated on the Effective Date shall be determined by the terms of any
such plans or programs. Employee may elect such insurance continuation or conversion as may be available under the applicable benefit
plan terms and applicable law for the period after the Termination Date so long as he makes a valid election for such continuation
and makes the payments necessary for continuation or conversion. Employee specifically acknowledges and agrees that he is not entitled
to any salary, severance, wages, commissions, options or other equity (or accelerated vesting thereof), benefits, insurance, or
other compensation from the CyrusOne Group, except as specifically set forth herein.

 

    2

     

    

 

		3.	Separation Pay and Benefits.

 

		A.	As provided by Sections 13(d) and 13(g) of the Employment Agreement, as modified by the Offer Letter,
in exchange for Employee’s timely execution and non-revocation of this Agreement and his continued compliance with its terms
and conditions and his other obligations to Employer (including, without limitation, the obligations imposed by Sections 7 and
11 of the Employment Agreement), Employer will pay or provide to Employee the following:

 

		i.	On the date that is sixty (60) days after the Termination Date, Employer shall pay Employee severance
of two million two hundred thousand dollars ($2,200.000), which is the sum of two times (a) Employee’s annual base salary
as of the Termination Date and (b) Employee’s annual bonus target in effect as of the Termination Date, in a single lump
sum cash payment.

 

		ii.	All of Employee’s outstanding
                                         stock options and equity awards previously issued by CyrusOne Group to Employee, as described
                                         in Exhibit A hereto, shall accelerate and become fully vested and immediately
                                         exercisable on the Termination Date and Employee shall be afforded an opportunity to
                                         exercise such options and awards until the earlier of (1) the latest exercise date specified
                                         by the applicable equity plan(s) and the award agreement(s), or (2) the last day of the
                                         Severance Period (as defined in Section 13(i)(i) of the Employment Agreement).

 

		iii.	If and to the extent applicable, an amount equal to the sum of (a) any forfeitable benefits of
Employee under any nonqualified ( i.e. , not qualified under Code Section 401(a)) pension, profit sharing, savings or deferred
compensation plan of any member of the CyrusOne Group which would have vested prior to the end of the Severance Period, plus (b)
any additional vested benefits which would have accrued for Employee under any nonqualified defined benefit pension plan, in each
case had had Employee’s employment not ended on the Termination Date. Payment of any such amounts will be made in accordance
with the terms of the applicable plan(s).

 

		iv.	If and to the extent applicable, an amount equal to the sum of (a) any forfeitable benefits of
Employee under any qualified ( i.e. , qualified under Code Section 401(a)) pension, profit sharing, 401(k) or deferred compensation
plan of any member of the CyrusOne Group which would have vested prior to the end of the Severance Period, plus (b) any additional
vested benefits which would have accrued for Employee under any qualified defined benefit pension plan, in each case had had Employee’s
employment not ended on the Termination Date. Any such amount shall be combined with the separation pay described in Section 3.A.i
above and paid by Employer from its general assets (and not under such plan(s) or a related trust) in a single lump sum sixty (60)
days following the Termination Date, provided this Agreement is then effective and irrevocable.

 

    3

     

    

 

		v.	An additional amount of twenty thousand nine hundred and twenty-three dollars ($20,923.00) in satisfaction
of Employer’s obligation to subsidize the costs of Employee’s continued group health and life insurance coverage during
the Severance Period, such amount to be aggregated with the separation pay described in Section 3.A.i above and paid by Employer
in a single lump sum sixty (60) days following the Termination Date, provided this Agreement is then effective and irrevocable.

 

		B.	The amounts in this Section 3 will be collectively referred to as the “Separation Pay and
Benefits,” which are amounts to which the Employee is not otherwise entitled. Employee acknowledges that, in the absence
of his execution of this Agreement as required by Sections 13(d) and 13(g) of the Employment Agreement, the Separation Pay and
Benefits would not otherwise be due to him.

 

		C.	The Separation Pay and Benefits provided in the form of cash will be processed and paid in accordance
with Section 13(d)(i) of the Employment Agreement via the normal payroll practices of Employer, and are subject to deductions for
payroll taxes, income tax withholding and other deductions required by law or authorized by Employee.

 

		D.	For the avoidance of doubt, the tabular summary attached hereto as Exhibit A describes the
outstanding equity awards which will vest according to their terms on February 28, 2020 and those to which the vesting acceleration
described in Section 3.A.ii above is applicable. If any equity award that is accelerated as provided in Section 3A.ii above is
deemed vested as of the Termination Date, but Employee revokes his agreement to those provisions of this Agreement releasing and
waiving Employee’s rights and claims under the ADEA, such equity acceleration will be immediately rescinded and revoked and
the underlying shares forfeited.

 

		4.	General Release.

 

		A.	Employee unconditionally, irrevocably and absolutely releases and discharges Employer, and any
and all parent and subsidiary corporations, divisions and affiliated corporations, partnerships or other affiliated entities of
Employer, past and present, as well as Employer’s past and present employees, officers, directors, partners, members, insurers,
employee benefit plans and fiduciaries, attorneys, agents, successors and assigns (collectively, “Released Parties”),
from all claims related in any way to the transactions or occurrences between them to date, to the fullest extent permitted by
law, including, but not limited to, Employee’s employment with Employer, the termination of Employee’s employment,
and all other losses, liabilities, claims, charges, demands and causes of action, known or unknown, suspected or unsuspected, arising
directly or indirectly out of or in any way connected with Employee’s employment with Employer that may be released under
applicable law (the “Released Claims”). This release is intended to have the broadest possible application and
includes, but is not limited to, any tort, contract, common law, constitutional or other statutory claims, including, but not limited
to alleged violations of federal, state or local law (including, without limitation, Title VII of the Civil Rights Act of 1964,
the Americans with Disabilities Act, the Age Discrimination in Employment Act of 1967, the Family and Medical Leave, the Civil
Rights Act of 1866, the Employee Retirement Income Security Act (with respect to unvested benefits), and Chapter 21 of the Texas
Labor Code, all as amended), and all claims for attorneys’ fees, costs and expenses. Notwithstanding the broad terms of this release, Employee is not releasing any claim or right to director and officer (D &
O) insurance coverage for any acts arising prior to the Termination Date.

 

    4

     

    

 

		B.	Notwithstanding the broad scope of the release set forth in this Section 4, this Agreement
is not intended to bar, and the defined term “Released Claims” does not include, any claims that, as a matter of law,
whether by statute or otherwise, may not be waived, such as claims for workers’ compensation benefits or unemployment insurance
benefits or Employee’s right to provide information to, participate in a proceeding before, or pursue relief from the National
Labor Relations Board, the Equal Employment Opportunity Commission (the “EEOC”), or the Securities and Exchange
Commission (“SEC”), and other similar federal, state, or local government agencies (collectively, “Government
Agencies”). Provided, however, that if Employee does pursue an administrative claim that may not be waived as a matter
of law, or such a claim is pursued on Employee’s behalf, Employee expressly waives Employee’s individual right to recovery
of any type, including monetary damages or reinstatement, for any such claim, except that this limitation on monetary recovery
will not apply to claims for workers’ compensation, unemployment insurance benefits, or proceedings before the SEC.

 

		C.	Employee acknowledges that Employee may discover facts or law different from, or in addition to,
the facts or law that Employee knows or believes to be true with respect to the Released Claims and agrees, nonetheless, that this
Agreement and the release contained in it shall be and remain effective in all respects notwithstanding such different or additional
facts or the discovery of them.

 

		D.	Subject to Section 4.B above, Employee declares and represents that Employee intends this Agreement
to be complete and not subject to any claim of mistake, and that the release herein expresses a full and complete release of the
Released Claims and Employee intends the release herein to be final and complete. Employee executes this Agreement with the full
knowledge that the release herein covers all Released Claims against the Released Parties, to the fullest extent permitted by law.

 

		E.	By execution of this Agreement, Employee represents that (a) Employee has been paid or otherwise
received all wages, vacation, bonuses, or other amounts owed to Employee by Employer, other than those specifically addressed in
this Agreement, and (b) Employee has not been denied any request for leave or accommodation to which Employee believes Employee
was legally entitled, and Employee was not otherwise deprived of any of Employee’s rights under the Family and Medical Leave
Act, the Americans with Disabilities Act, or any similar state or local statute.

 

    5

     

    

 

 

	5.	Covenant Not to Sue. Subject to Section 4.B above or as otherwise provided in this Agreement,
Employee agrees that Employee is precluded from and is waiving all rights to sue based on the Released Claims or to obtain equitable,
remedial or punitive relief from any or all of the Released Parties of any kind whatsoever based on the Released Claims, including,
without limitation, reinstatement, back pay, front pay, attorneys’ fees and any form of injunctive relief. Employee represents
that, as of the date of Employee’s signing this Agreement, Employee has not filed any lawsuits, charges, complaints, petitions,
claims or other accusatory pleadings against the Employer or any of the other Released Parties in any court or with any governmental
agency and, to the best of Employee’s knowledge, no person or entity has filed any such lawsuits, charges, complaints, petitions,
claims or other accusatory pleadings against the Employer or any of the other Released Parties on Employee’s behalf. Employee
further represents that Employee has not assigned, or purported to assign, Employee’s right to file any such lawsuits, charges,
complaints, petitions, claims or other accusatory pleadings against the Employer or any of the other Released Parties to any other
person or entity.

 

	6.	Older Workers’ Benefit Protection Act. This Agreement is intended to satisfy the requirements
of the Older Workers’ Benefit Protection Act, 29 U.S.C. sec. 626(f). Employee is advised to consult with an attorney before
executing this Agreement.

 

		A.	ADEA Release and Waiver. By entering into this Agreement, Employee is giving up important
rights, including, but not limited to, any rights and claims that may exist under the Age Discrimination in Employment Act of 1967,
as amended (the “ADEA”).

 

		B.	Acknowledgments. Employee acknowledges and agrees that (a) Employee has read and understands
the terms of this Agreement; (b) Employee has been advised in writing, by this Agreement, to consult with an attorney before executing
this Agreement; (c) Employee has obtained and considered such legal counsel as Employee deems necessary; and (d) by signing this
Agreement, Employee acknowledges that Employee does so freely, knowingly, and voluntarily.

 

		C.	Time to Consider. Employee has 21 days to consider whether or not to enter into this Agreement
and return a signed copy to Employer (although Employee may elect not to use the full 21 day period at Employee’s option).
Any change(s) made to this Agreement by the parties during the 21-day consideration period will not restart the running of the
21-day consideration period. Employer’s offer will expire at the end of the 21-day consideration period

 

		D.	Revocation Right. For a period of seven (7) calendar days following Employee’s execution
of this Agreement, Employee may revoke Employee’s agreement to those provisions of this Agreement releasing and waiving Employee’s
rights and claims under the ADEA. If Employee chooses to revoke the Agreement, Employee must deliver a written notice of revocation
to Kellie Teal-Guess, EVP – Chief People Officer at 2850 N. Harwood St. Suite 2200, Dallas, TX 75201, kellie@cyrusone.com.
Any such revocation must be actually received by Employer within the Revocation Period or it will be null and void. Because of
Employee’s right to revoke Employee’s agreement to those provisions of this Agreement releasing and waiving Employee’s
rights and claims under the ADEA, those provisions shall not become effective or enforceable until the revocation period has expired
without Employee exercising the right to revoke.

 

    6

     

    

 

		E.	Effect of Revocation. If Employee exercises Employee’s right to revoke Employee’s
agreement to those provisions of this Agreement releasing and waiving Employee’s rights and claims under the ADEA, the Separation
Pay and Benefits shall be reduced to one thousand dollars ($1,000.00) in total and Employee shall not be entitled to the balance
of the Separation Pay and Benefits as detailed above. Employee acknowledges and agrees that the reduced Separation Pay and Benefits
will constitute full and adequate consideration for Employee’s release of any and all non-ADEA claims in this Agreement as
detailed in Section 4 above.

 

		F.	Effective Date. With the exception of the provisions of this Agreement releasing and waiving
Employee’s rights and claims under the ADEA, all other terms and conditions of this Agreement shall be binding and enforceable
immediately upon Employee’s execution of this Agreement, and shall remain effective regardless of whether Employee revokes
Employee’s agreement to those provisions of this Agreement releasing and waiving Employee’s rights and claims under
the ADEA.

 

		G.	Preserved Rights of Employee. This Agreement does not waive or release any rights or claims
that Employee may have under the ADEA that arise after the execution of this Agreement. In addition, this Agreement does not prohibit
Employee from challenging the validity of this Agreement’s waiver and release of claims under the ADEA.

 

		H.	Nondisclosure. Before CyrusOne’s public disclosure of this Agreement, Employee will
not disclose the terms of this Agreement to any non-party, except that Employee may disclose the terms of this Agreement to any
government agency or as necessary to secure advice from his counsel, accountants or tax advisors. Before CyrusOne’s public
disclosure of this Agreement, Employee will take appropriate steps to ensure that his counsel, accountants and tax advisors are
aware of and comply with this confidentiality provision, and Employee assumes the risk of and shall be accountable for any breach
of this confidentiality provision occasioned by any act or omission of any person to whom the agreement is disclosed.

 

			The federal Defend Trade Secrets Act of 2016 (the “Act”) provides immunity from
                                                                              liability in certain circumstances to Employer’s employees, contractors, and consultants for limited disclosures of
                                                                              Employer “trade secrets,” as defined by the Act. Specifically, Employer’s employees, contractors, and
                                                                              consultants may disclose trade secrets: (1) in confidence, either directly or indirectly, to a federal, state, or local
                                                                              government official, or to an attorney, “solely for the purpose of reporting or investigating a suspected violation of
                                                                              law,” or (2) “in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made
                                                                              under seal.” Additionally, employees, contractors, and consultants who file lawsuits for retaliation by an employer for
                                                                              reporting a suspected violation of law may use and disclose related trade secrets in the following manner: (1) the individual
                                                                              may disclose the trade secret to his/her attorney, and (2) the individual may use the information in the court proceeding, as
                                                                              long as the individual files any document containing the trade secret under seal and does not otherwise disclose the trade
                                                                              secret “except pursuant to court order.”

 

    7

     

    

 

	7.	Return of Property. Employee agrees and represents that Employee has returned to Employer,
or will return before the Termination Date, and retained no copies of, any and all CyrusOne Group property, including but not limited
to files, manuals, business records, customer records, correspondence, software and related program passwords, computer printouts
and disks, electronically stored information (“ESI”) that resides on any of Employee’s personal electronic
devices, keys, equipment, and any and all other documents or property which Employee had possession of, access to, or control over
during the course of Employee’s employment with CyrusOne Group or subsequent thereto, including but not limited to any and
all documents of CyrusOne Group and any documents removed from or copied from other documents contained in CyrusOne Group’s
files. Employee further acknowledges and agrees that all of the documents or other tangible things to which Employee has had possession
of, access to, or control over during the course of or subsequent to Employee’s employment with CyrusOne Group, including
but not limited to all documents or other tangible things, pertaining to any specific business transactions in which CyrusOne Group
was involved, or to any customers and suppliers of CyrusOne Group, or to the business operations of CyrusOne Group are considered
confidential and have been returned to CyrusOne Group. In the event Employee is in possession of ESI that resides on any of Employee’s
personal electronic devices (including but not limited to a personal computer, iPhone and iPad) upon returning CyrusOne Group’s
ESI to CyrusOne Group, Employee agrees and represents that all CyrusOne Group ESI has been deleted from all personal electronic
devices and is inaccessible to Employee or any other party having access to those devices. Employee represents that CyrusOne Group
property including CyrusOne Group ESI has not been copied and/or distributed to anyone who is not an authorized representative
of CyrusOne Group. Employee will provide, upon Employer’s request, access to his personal computer, iPhone and iPad to Employer
so that Employer can retrieve, delete and/or confirm deletion of the CyrusOne Group’s ESI from such devices. Notwithstanding
the foregoing, Employer will not consider a breach of this provision any inadvertent immaterial failure of Employee to return all
property and ESI to CyrusOne Group if Employee diligently seeks to return all such property as soon as possible after discovery
and maintains the confidentiality of such property and ESI.

 

	8.	Restrictive Covenants. This Agreement does not supersede any prior agreement or promise
between Employee and any of the Released Parties regarding confidentiality, non-competition, non-disclosure or non-solicitation,
and any and all such agreements and promises shall remain in full force and effect, and Employee acknowledges and reaffirms his
post-employment obligations and other restrictive covenants that are set forth in the Employment Agreement (Sections 7, 8, 9, 10,
11, and 12), the Plan and the awards issued to him thereunder; provided, however, that notwithstanding any provision
contained in the Employment Agreement, the Plan or the awards issued to Employee thereunder, Employee is not restricted in any
way from communicating with Government Agencies or otherwise participating in any investigation or proceeding that may be conducted
by any Government Agency, including providing documents or other information, without notice to Employer. If Employee breaches
any of such covenants, Employee must repay to Employer the amounts described in Section 3 of this Agreement, including the value
of any equity awards that become vested and gain upon exercise of any options that become vested, within 10 days after demand by
Employer, and Employer shall be entitled, upon application to a court of competent jurisdiction, to obtain injunctive or other
relief to enforce such promises and covenants.

 

    8

     

    

 

	9.	Consideration of Medicare’s Interests. Employee affirms, covenants, and warrants Employee
is not a Medicare beneficiary and is not currently receiving, has not received in the past, will not have received at the time
the Separation Pay and Benefits is due under this Agreement, is not entitled to, is not eligible for, and has not applied for or
sought Social Security Disability or Medicare benefits. In the event any statement in the preceding sentence is incorrect (for
example, but not limited to, if Employee is a Medicare beneficiary, etc.), the following sentences of this paragraph apply. Employee
affirms, covenants, and warrants Employee has made no claim for illness or injury against, nor is Employee aware of any facts supporting
any claim against, the Released Parties under which the Released Parties could be liable for medical expenses incurred by Employee
before or after the execution of this Agreement. Furthermore, Employee is aware of no medical expenses that Medicare has paid and
for which the Released Parties are or could be liable now or in the future. Employee agrees and affirms that, to the best of Employee’s
knowledge, no liens of any governmental entities, including those for Medicare conditional payments, exist. Employee will indemnify,
defend, and hold the Released Parties harmless from Medicare claims, liens, damages, conditional payments, and rights to payment,
if any, including attorneys’ fees, and Employee further agrees to waive any and all future private causes of action for damages
pursuant to 42 U.S.C. § 1395y(b)(3)(A) et seq.

 

	10.	Indemnification. Employee agrees to hold the Released Parties harmless from, and to defend
and indemnify the Released Parties from and against, all further claims, cross-claims, third-party claims, demands, costs, complaints,
obligations, causes of action, damages, judgments, liability, contribution, or indemnity related in any way to the allegations
that were or could have been made by Employee with respect to the claims and causes of action released as part of this Agreement,
as well as any claims that may be made indirectly against the Released Parties for contribution, indemnity, or otherwise by any
third party from whom or which Employee seeks relief or damages, directly or indirectly, for the same claims and/or causes of action
released as part of this Agreement, regardless of whether such claims are caused in whole or in part by the negligence, acts, or
omissions of any of the Released Parties.

 

			Employee shall be responsible for all federal, state, and local tax liability, if any, that
                                                                          may attach to amounts payable or other consideration given under this Agreement, and will defend, indemnify, and hold the
                                                                          Released Parties harmless from and against, and will reimburse the Released Parties for, any and all liability of whatever
                                                                          kind incurred by the Released Parties as a result of any tax obligations of Employee, including but not limited to taxes,
                                                                          levies, assessments, penalties, fines, interest, attorneys’ fees, and costs. Employee warrants that Employee is
                                                                          not relying on the judgment or advice of any of the Released Parties or legal counsel concerning the tax consequences, if
                                                                          any, of this Agreement.

 

    9

     

    

 

	11.	Nondisparagement. Employee agrees that he will not, directly or indirectly, make to third
parties any oral, written, or electronic statement which directly or indirectly impugns the quality or integrity of the CyrusOne
Group, or any other disparaging or derogatory remarks about the CyrusOne Group; provided, however, that this obligation shall not
preclude Employee from (i) providing information to government agencies, (ii) responding to inquiries by any person or entity through
a subpoena or other legal process, (iii) testifying under oath in a legal proceeding or (iv) making other disclosures as required
by applicable law.

 

	12.	Passwords. Upon request, Employee agrees to provide all User IDs and Passwords used by Employee,
and of any other party of which he is aware, to access CyrusOne Group ESI on CyrusOne Group computers, electronic devices, and
software.

 

	13.	Dispute Resolution. Except as otherwise provided in Section 8 of this Agreement, Employer
and Employee agree that all disputes, controversies or claims between them arising out of or relating to this Agreement shall be
submitted to arbitration pursuant to the terms and conditions set forth in the Employment Agreement.

 

	14.	No Admissions. By entering into this Agreement, the Released Parties make no admission that
they have engaged, or are now engaging, in any unlawful conduct. The parties understand and acknowledge that this Agreement is
not an admission of liability and shall not be used or construed as such in any legal or administrative proceeding.

 

	15.	Full Defense. This Agreement may be pled as a full and complete defense to, and may be used
as a basis for an injunction against, any action, suit or other proceeding that may be prosecuted, instituted or attempted by Employee
in breach hereof.

 

	16.	No Waiver. Any failure or forbearance by Employer or Employee to exercise any right or remedy
with respect to enforcement of this Agreement shall not be construed as a waiver of Employer’s or Employee’s rights
or remedies, nor shall such failure or forbearance operate to modify this Agreement or such instruments in the absence of a writing.
No waiver of any of the terms of this Agreement shall be valid unless in writing and signed by both parties to this Agreement.
The waiver by Employer or Employee of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent
breach, nor shall any waiver operate or be construed as a rescission of this Agreement.

 

	17.	Successors. The provisions of this Agreement shall inure to the benefit of Employer, its
successors and assigns, and shall be binding upon Employee and his heirs, administrators and assigns.

 

	18.	Acknowledgement. The parties represent that they have read this Agreement, that they understand
all of its terms, and that in executing this Agreement they do not rely and have not relied upon any representations or statements
made by the other with regard to the subject matter, basis, or effect of the Agreement.

 

	19.	Severability; Modification. Employee and Employer further agree that if any provision of
this Agreement is held to be unenforceable, such provision shall be considered to be separate, distinct, and severable from the
other remaining provisions of this Agreement, and shall not affect the validity or enforceability of such other remaining provisions.
If this Agreement is held to be unenforceable as written, but may be made enforceable by limitation, then such provision shall
be enforceable to the maximum extent permitted by applicable law.

 

    10

     

    

 

	20.	Entire Agreement. Employee and Employer finally agree that, except for the provisions of
any other agreement referred to herein as surviving this Agreement, this Agreement: (i) contains and constitutes the entire understanding
and agreement between them with respect to its subject matter; (ii) supersedes and cancels any previous negotiations, agreements,
commitments, and writings with respect to that subject matter; (iii) may not be released, discharged, abandoned, supplemented,
changed or modified in any manner except by a writing of concurrent or subsequent date signed by both parties; and (iv) shall be
construed and enforced in accordance with the laws of the State of Texas, without regard to its conflicts of laws provisions. THE
PARTIES TO THIS AGREEMENT HAVE READ THE FOREGOING AGREEMENT AND FULLY UNDERSTAND EACH AND EVERY PROVISION CONTAINED THEREIN. THE
PARTIES HAVE OBTAINED AND CONSIDERED SUCH LEGAL COUNSEL AS EACH DEEMS NECESSARY TO ENTER INTO THIS AGREEMENT. WHEREFORE, THE PARTIES
HAVE EXECUTED THIS AGREEMENT ON THE DATES SHOWN BELOW.

 

 

	 	EMPLOYEE
	 	 
	 	/s/ Venkatesh S. Durvasula
	 	Dated:	January 13, 2020
	 	 
	 	CYRUSONE LLC
	 	 
	 	By:	 /s/ Gary J. Wojtaszek
	 	Its:	 Chief Executive Officer
	 	Dated:	January 16, 2020

 

    11

     

    

 

EXHIBIT A –
SUMMARY OF EQUITY AWARDS

 

	Grant Type	Shares Outstanding	Vested

 Shares	Shares Vesting on February 28, 2020	Additional Shares Vesting Per

 Section 3.A.ii
	Restricted Stock Units / RSUPAY	7,864	0	2,622	5,242
	Restricted Stock Units / RSUPAY	3,898	0	1,949	1,949
	Restricted Stock Units / RSUPAY	1,558	0	1,558	0
	Performance Units / TSR	23,590	0	0	23,590
	Performance Units / TSR	17,541	0	0	17,541
	Performance Units / TSR	14,024	9,349	18,699	0

 

Data current as of January 13, 2020

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]